{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3907.460","value":"8795.769"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Plasma pharmacokinetics (Cmax) of unchanged bendamustine","dispersionType":"Standard Deviation","groups":[{"description":"SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.","id":"OG000","title":"SyB L-0501 + Prednisolone"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"On Day 1 only","title":"Pharmacokinetic Parameters (Cmax)","type":"SECONDARY","unitOfMeasure":"ng/mL"}